A sign stands in front of a Abbvie facility in Cambridge, Massachusetts.
Brian Snyder | Reuters
A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.
The booming market for weight loss medicines has won a new potential competitor.
Abbvie Said on Monday that it would pay up to 2.2 billion US dollars for the development of experimental obstacle medication of the Danish drug makers Gubra and mark its late foray into the segment.
As part of the contract, the pharmaceutical Gubra will pay 350 million US dollars in advance. Abbvie will also pay up to almost 1.9 billion US dollars if the medication fulfills certain development and sales milestones.
Gubra, which offers pre-clinical contract research and peptide-based drug discovery services, can receive certain license fees for the global net conversion of the drug called GUB014295. Gubra's shares made 15% higher on Monday after the license agreement was announced.
Here is what is important to know about the drug: it is an injection that imylin imitates, another intestinal hormone than the existing obesity medication on the market goal.
Amylin activates signals for the brain that suppress the appetite and reduce food intake, says Abbvie. The hormone also slows down the so -called gastric emptying or the process through which the stomach contents are moved into the small intestine.
Novo Nordisk'S Blockbuster-Fettlebiglubkeitung Wegovy Ahmt a hormone called GLP-1 to tamp the appetite and regulate the blood sugar while Eli LillyYour own medicine is aimed at GLP-1 and another hormone called Gip.
Some companies, including Novo Nordisk, Zealand Pharma, Astrazeneca And Structure therapyDevelop products that aim at Amylin. Some of these drugs are still in development as Gubras Medicine such as Zealand's petrelintide, but it is still too early to know which is most effective for weight loss.
Some pharmaceutical manufacturers believe that alignment on Amylin could reduce gastrointestinal side effects that are typically observed with treatments that aim at GLP-1 and can lead to less muscle loss than existing medication. However, these effects must be demonstrated in clinical studies.
In a Research Note on Monday, the BMO analyst Evan Seigerman said “All-in, we are positive about the deal” for Abbvie. He said that the company's entry into the obesity market could come to other areas of his business such as inflammation and aesthetics.
For example, researchers examine the inflammatory advantages of obesity medications for diseases such as a serious form of liver diseases, cardiovascular results and Alzheimer's, including, Seigerman wrote.
“We see an opportunity for Abbvie to use their specialist knowledge in this area in order to better understand these potential advantages,” he added.
An obesity medication could also complement Abbvie's aesthetic business, which, according to Seigerman, offers Botox, other facial injections, skin care and body contouring.
In particular, the deal comes when Abbvie is looking for the Mega Blockbuster Autoimmune Medicine Humira after his next best -selling medication.
“Our partnership with Gubra marks our entry into the field, which offers a convincing opportunity that is based on the potential to question the patient needs and at the same time promotes the long -term growth of our company,” said Abbvie, Robert Michael, a little more than six months ago, in a statement on Monday.
However, the deal could be “potentially negative” for structure therapeutic agents, said Seogerman.
This biotech company is still looking for potential partnerships with large pharmaceutical companies to further develop and commercialize its experimental GLP-1 and amylin products.
Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.
The latest in the healthcare system Tech: AI is the focus of the HIMSS conference in Vegas starts
Participants of the Himss in Orlando, Florida 2024.
With the kind permission of Himss
This is Ashley, the live from Las Vegas, Nevada, reports!
I am here on site at the Himss Global Health Conference and exhibition 2025 here, where the managers of health and technology collide their latest and greatest innovations. The exhibition floor opens today, but there have already been a number of announcements, especially nearby – yes, they guessed it – artificial intelligence.
Here is everything you need to know:
- Microsoft On Monday, a new AI assistant of the healthcare system called Dragon Copilot announced, which is based on his existing dictation and ambient hearing. It is the company's latest move to stand out on the hard -fought AI writing market, which has grown immensely in recent years. Read CNBC's reporting here.
- Amazon On Monday it said that Amazon brings a health of the NYU Langone, which means that the patients will be able to check in appointments by simply scanning their palm. The service helps the NYU Langone to speed up the registration process and alleviate the administrative workload. Read CNBC's reporting here.
- Google On Monday, new generative AI functions in its platform -Vertex -KI search terminated for health care, with which developers can train and provide various AI models and applications. The company said Gemini 2.0 is now available as one of the models, and a new function called Visual Q&A will enable doctors to search diagrams, tables and diagrams.
- Salesforce On Friday it said that Agentforce for Health, a number of prefabricated actions and skills with which providers, payers and other AI agents can easily build. Agentforce for Health specializes in public health, clinical skills and access to patients and services. It happens that Salesforce announced Agentforce, an AI agent service in September.
- Wolters Kluwer Health announced this week that the company will integrate its medical database into the AI-Skribing tool from Suki and the health agency service in the Microsoft Copilot Studio. Ideally, this makes it easier for doctors to use these platforms to absorb trustworthy medical resources faster and easier.
- Give health care On Tuesday, he announced a new portfolio of Cloud Imaging software solutions called Genesis. The portfolio comprises four different offers, with which providers can manage and store large quantities of medical images more easily, according to the company.
A lot more will come this week (provided that I am not completely lost in the Venetian). So make sure that you keep pace with the reporting of CNBC. I will have more about the big topics and snack bars that I will hear in the next few days.
Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.
Comments are closed.